<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04606394</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT04606394</nct_id>
  </id_info>
  <brief_title>Peak Inspiratory Flow (PIF) in COPD</brief_title>
  <official_title>Peak Inspiratory Flow (PIF) in COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulmonary Research Institute of Southeast Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pulmonary Research Institute of Southeast Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether PIF is clinically important when using the&#xD;
      Ellipta DPI device. In addition, the study will validate the best/most clinically appropriate&#xD;
      way to perform a PIF maneuver, to determine the testing capabilities of the preferred PIF&#xD;
      maneuver and to relate this PIF measurement to meaningful clinical outcomes in COPD patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design and Methods Rationale&#xD;
&#xD;
        -  The expected FEV1 response to a bronchodilator is uncertain as multiple factors&#xD;
           influence this measure, including severity of disease, day to day variability, varying&#xD;
           reversibility in COPD patients, the delivery of the drug to a patient and the&#xD;
           effectiveness of the medication delivered. Thus, the measurement of an acute&#xD;
           bronchodilator response after delivering a long acting bronchodilator may not identify&#xD;
           whether a medication has been effectively delivered to a patient.&#xD;
&#xD;
        -  However, if a long acting bronchodilator has not been effectively delivered to the lung,&#xD;
           then subsequent delivery of a short acting bronchodilator should produce a significant&#xD;
           additional bronchodilator response. On the other hand, if a long acting bronchodilator&#xD;
           has been effectively delivered to the lung, then subsequent delivery of a short acting&#xD;
           bronchodilator should not produce any further significant bronchodilation.&#xD;
&#xD;
        -  Based on this rationale, comparison of the acute bronchodilator response to a short&#xD;
           acting bronchodilator after receiving a long acting should identify whether drug&#xD;
           delivery is ineffective in a selected patient population, irrespective of baseline FEV1&#xD;
           and of any partial response to the long acting bronchodilator. Comparison of the short&#xD;
           acting bronchodilator measurement between patient groups with differing PIF thresholds&#xD;
           should identify whether PIF has an impact of drug delivery of a long acting&#xD;
           bronchodilator via a DPI.&#xD;
&#xD;
        -  Open label design comparing the acute bronchodilator response after delivery of a long&#xD;
           acting bronchodilator via Ellipta DPI in patients with normal, suboptimal and minimal&#xD;
           PIF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label comparative design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 Response (to Ventolin Post Trelegy)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change in FEV1 Pre versus Post Ventolin administration after having been administered Trelegy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PIF (pre Trelegy)</measure>
    <time_frame>2 weeks</time_frame>
    <description>PIF measured prior to the administration of Trelegy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of PIF to FEV1 Response</measure>
    <time_frame>2 weeks</time_frame>
    <description>Correlation of PIF (pre Trelegy) to FEV1 Response (to Ventolin Post Trelegy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optimal PIF</measure>
    <time_frame>2 weeks</time_frame>
    <description>PIF measured while using 4 different inhalation instructions (pre Trelegy) correlated to FEV1 Response (to Ventolin Post Trelegy)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Open label treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects receive Trelegy and Ventolin for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trelegy Ellipta 100/62.5/25Mcg Inh 30D</intervention_name>
    <description>Administration of Trelegy in all patients</description>
    <arm_group_label>Open label treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ventolin 90Mcg/Actuation Inhalation Aerosol</intervention_name>
    <description>2 hours after the administration of Trelegy, administer Ventolin in all patients</description>
    <arm_group_label>Open label treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  smoking history &gt;10 pack years&#xD;
&#xD;
          -  pre-bronchodilator FEV1 &lt;60% predicted&#xD;
&#xD;
          -  post-bronchodilator FEV1/FVC &lt;70%&#xD;
&#xD;
          -  female participants are eligible to participate if they are not pregnant, not&#xD;
             breastfeeding, and at least one of the following conditions applies:&#xD;
&#xD;
          -  not a woman of childbearing potential OR&#xD;
&#xD;
          -  agree to follow the contraceptive guidance during the treatment period and until the&#xD;
             safety follow-up contact after the last dose of study treatment&#xD;
&#xD;
          -  stratification requiring at least 1/3 of patients having a PIF of &lt; 60L/min (AM&#xD;
             pre-dose based on using the level 2 InCheck Dial resistance setting with a sharp&#xD;
             maximal effort starting after exhaling fully)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any subject with unstable disease, including&#xD;
&#xD;
          -  COPD exacerbation in the last 6 weeks&#xD;
&#xD;
          -  upper respiratory tract in in the last 4 weeks&#xD;
&#xD;
          -  COPD or upper respiratory tract infection during run-in (subjects may be re-screened x&#xD;
             1 when stable after an acute event)&#xD;
&#xD;
          -  pulmonary disease other than COPD&#xD;
&#xD;
          -  any lung resection&#xD;
&#xD;
          -  unstable cardiac conditions (at the discretion of the investigator)&#xD;
&#xD;
          -  other unstable medical conditions (at the discretion of the investigator)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary T Ferguson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pulmonary Research Institute of Southeast Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary T Ferguson, MD</last_name>
    <phone>248-478-6561</phone>
    <email>garytferguson@msn.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brooke Grubb, BS</last_name>
    <phone>248-478-6561</phone>
    <email>pulmonary.research7@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pulmonary Research Institute of Southeast Michigan</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary T Ferguson, MD</last_name>
      <phone>248-478-6561</phone>
      <email>garytferguson@msn.com</email>
    </contact>
    <contact_backup>
      <last_name>Brooke Grubb, BS</last_name>
      <phone>248-478-6561</phone>
      <email>pulmonary.research7@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DPI</keyword>
  <keyword>PIF</keyword>
  <keyword>FEV1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

